The quarter cleared a modest published bar. The available consensus was approximately $0.24 for quarterly EPS and $329.7 million for revenue; Guardian delivered $0.29 of adjusted EPS and $351.8 million of revenue. That implies a meaningful revenue beat and roughly a 21% adjusted-EPS beat, although the estimate set was limited.
| Metric | Q2 2025 | Q2 2026 | Change / comparison |
|---|---|---|---|
| Revenue | $344.3M | $351.8M | +2.2% year over year (Condensed Consolidated Statements of Operations) |
| Adjusted EBITDA | $25.0M | $29.7M | +18.9%; margin rose from 7.2% to 8.4% (Adjusted EBITDA reconciliation) |
| Net income | $8.8M | $22.1M | Includes an $8.5M payor settlement (Condensed Consolidated Statements of Operations; Adjusted EBITDA reconciliation) |
| Diluted EPS | $0.14 | $0.34 | GAAP EPS (Condensed Consolidated Statements of Operations) |
| Adjusted EPS | $0.23 | $0.29 | Non-GAAP EPS (Adjusted EBITDA and Adjusted EPS reconciliation) |
| Full-year revenue guidance | — | $1.43B–$1.45B | Raised from $1.40B–$1.42B (FY 2026 Outlook) |
| Full-year adjusted EBITDA guidance | — | $129M–$131M | Raised from $122M–$127M (FY 2026 Outlook) |
The quality of the operating result was better than the headline revenue growth suggests. Residents served grew 8% to roughly 210,000, while reported revenue rose only 2% because of IRA-related pricing reductions. More importantly, adjusted EBITDA increased nearly 19% and margin expanded 120 basis points, supporting the company’s claim that purchasing leverage and operating efficiency are improving (Second Quarter Financial Results; Adjusted EBITDA reconciliation). The filing does not provide a reliable published consensus for adjusted EBITDA, so the clearest expectation signal is the guidance increase rather than a quantified EBITDA surprise.
The large GAAP earnings jump overstates the underlying improvement. Net income benefited from the $8.5 million cash settlement of a payor dispute, which was excluded from adjusted results. Stripping that item out, adjusted net income still rose to $18.5 million from $14.5 million and adjusted EPS increased to $0.29 from $0.23, but the recurring earnings improvement is considerably smaller than the reported GAAP EPS jump (Adjusted EBITDA and Adjusted EPS reconciliation).
Management raised the forward bar instead of merely reaffirming it. Revenue guidance increased by $30 million at the midpoint, while adjusted EBITDA guidance increased by $5.5 million at the midpoint (FY 2026 Outlook). Because the revised outlook excludes future acquisitions, the Wellness Concepts acquisition and new Lexington, Kentucky greenfield pharmacy add strategic growth capacity beyond the raised organic outlook, though the filing gives no quantified contribution from either.
Net read: clearly better than expected, with the main caveat that one-time settlement income clouds GAAP earnings. The combination of a revenue and adjusted-EPS beat, stronger core margin performance, and higher full-year guidance is a broad positive surprise; the recurring-business signal is strongest in adjusted EBITDA and margin, not in the headline net-income increase.
Read the original 8-K on SEC EDGAR ↗